FIXX INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

Source - MicroSmallCap

San Francisco, California–(Newsfile Corp. – October 16, 2020) –  Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.

Relevant Period: Before July 21, 2020
Visit: www.hbsslaw.com/investor-fraud/FIXX
Contact An Attorney Now: FIXX@hbsslaw.com
844-916-0895

Homology Medicines, Inc. (FIXX) Investigation:

Homology Medicines is a Boston, MA-based gene therapy company focused on curing rare genetic diseases.

The investigation centers on the accuracy of Homology Medicines’ statements concerning the efficacy of its ...

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email